Increased interleukin-6 and high-sensitivity C-reactive protein levels in pediatric epilepsy patients with frequent, refractory generalized motor seizures  by Ishikawa, Nobustune et al.
Seizure 25 (2015) 136–140Increased interleukin-6 and high-sensitivity C-reactive protein levels
in pediatric epilepsy patients with frequent, refractory generalized
motor seizures
Nobustune Ishikawa *, Yoshiyuki Kobayashi, Yuji Fujii, Masao Kobayashi
Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan
A R T I C L E I N F O
Article history:
Received 8 August 2014
Received in revised form 7 October 2014








A B S T R A C T
Purpose: Recently, it was found that chronic inﬂammation contributes to the pathomechanism of diverse
chronic diseases in various organs. There is accumulating evidence that inﬂammatory processes affect
the pathophysiology of epilepsy. We investigated inﬂammatory markers to determine the chronic
inﬂammatory process underlying the pathophysiology of intractable epilepsy presenting with frequent
motor seizures in children.
Method: In total, 29 patients with epilepsy and 15 children as control subjects were enrolled. Patients
were divided into the DS (daily generalized motor seizures) and the IS (intermittent seizures) groups.
Blood levels of serum high-sensitivity C-reactive protein (hs-CRP), plasma pentraxin 3 (PTX3), serum
tumor necrosis factor (TNF)-a, interleukin (IL)-6, and IL-b1 were evaluated in all participants.
Results: Hs-CRP levels were signiﬁcantly higher in the DS group (0.149  0.161 mg/dL) than in either the
IS or control group (0.0156  0.0136 and 0.0253  0.0288 mg/dL, p < 0.005 and p < 0.05, respectively),
while there was no signiﬁcant difference between the IS and control groups. The IL-6 level was also
signiﬁcantly higher in the DS group (8.022  0.161 pg/mL) than in either the IS or the control group
(7.783  0.0563 and 7.864  0.072 pg/mL; p < 0.005 and p < 0.05, respectively). There were no signiﬁcant
differences in PTX3, TNF-a, or IL-1b levels.
Conclusion: Our results suggest that daily generalized motor seizures result in elevated IL-6 levels,
leading to increased CRP. A systemic inﬂammatory response in intractable patients with frequent
generalized motor seizures may affect their prognosis. We may need therapeutic strategies, including
methods to control the inﬂammatory process, to treat intractable epilepsy.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Chronic inﬂammatory processes have been shown to play crucial
roles in diverse chronic diseases, such as cardiovascular, respiratory,
renal, and neurological diseases, in addition to the traditionally
recognized ‘inﬂammatory’ diseases.1–7 High-sensitivity C-reactive
protein (hs-CRP) is a useful biomarker to detect chronic, subtle
inﬂammation, which is not detected by conventional CRP values.8,9
Pentraxin 3 (PTX3), a member of the pentraxin protein family, has
been identiﬁed recently as a ‘new’ inﬂammatory marker. PTX3 is
elevated mainly in cardiovascular diseases, although its elevation in
some other chronic diseases has also been reported.10–12* Corresponding author at: Department of Pediatrics, Hiroshima University
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reRecently, accumulating evidence from experimental models
and human studies has suggested that the pathophysiology of
epilepsy also involves inﬂammatory process(es).13–15 In previous
studies, diverse cytokines have been evaluated in certain types of
epilepsy,16–21 while there have been few reports regarding other
inﬂammatory markers. CRP levels were higher in partial second-
arily generalized tonic–clonic seizures than in other types of
partial seizures. There was a trend toward increased CRP
concentrations in patients with recent tonic–clonic seizures and
secondarily generalized seizures compared with control sub-
jects.22 PTX3 has been suggested to be synthesized in the brain
after seizures and to exert a protective role against seizure-induced
neurodegeneration.23
Intractable, frequent seizures at an early stage may be harmful
in the brain development due to interference with developmental
programs.24,25 Intractable, frequent seizures at an early stage may
be harmful in the brain development due to interference with
developmental programs.26,27served.
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underlie the pathophysiology of intractable epilepsy presenting
with frequent seizures in children. We considered that daily
frequent motor seizures may cause more inﬂammation than do
less frequent seizures. Thus, we investigated inﬂammatory
markers, including hs-CRP, PTX3, tumor necrosis factor (TNF)-a,
interleukin (IL)-6, and IL-b1, in the blood of patients with daily
frequent seizures, particularly generalized motor seizures, com-
pared with those with less frequent seizures and control subjects.
2. Materials and methods
2.1. Patients and controls
From June 2013 to February 2014, 29 patients with epilepsy
(14 boys, 15 girls) and 15 children (7 boys, 8 girls) as control
subjects were enrolled. The control group consisted of patients
from Hiroshima University Hospital without epilepsy, fever, acute
illness, or any other immune-mediated disorders. Epilepsy
patients were diagnosed based on medical history and electro-
clinical (seizure semiology and EEG/video-EEG) and neuroimaging
ﬁndings. They were divided into two groups: those who had daily
generalized motor seizures (epileptic spasms, tonic seizures,
secondarily generalized tonic–clonic seizures, and myoclonic
seizures) and those who had intermittent (less than daily) seizures.
Patients in the daily seizure (DS) group (n = 12; 7 boys, 5 girls)
had more than three seizures/day and those in the intermittent
seizures (IS) group (n = 17; 7 boys, 10 girls) had less than one seizure/
month. All patients in the DS group were monitored using a video-
electroencephalogram (EEG) monitoring system for more than 24 h,
and their seizure types and frequencies were conﬁrmed by epilepsy
specialists with clinical information. Video-EEG monitoring was
performed using 21 scalp electrodes, which were placed according
to the international ‘‘1–20’’ system, with electromyogram (EMG)
sensors placed on the bilateral deltoid muscles.
The mean ages of the children in the DS, IS, and control groups
were 4.54  3.00, 6.44  3.41, and 5.49  4.37 years, respectively. No
statistically signiﬁcant differences in age, gender, body mass index, or
treatment duration were observed among the three groups (Table 1,
all p > 0.05). No patient in the DS or IS group had undergone any
immune-related treatments, such as adrenocorticotropic hormone
(ACTH), glucocorticoid, or immunoglobulin therapies, for at least
6 months before blood sampling.
This study was approved by the Hiroshima University
Institutional Review Board. Written informed consent was
obtained from the parents of each child.
2.2. Determination of serum hs-CRP, plasma PTX3, serum TNF-a, IL-6,
and IL-1b levels
Serum and plasma samples were collected from the children
who had no symptoms of infectious or inﬂammatory diseases.
Peripheral venous blood was withdrawn from each subject andTable 1
Clinical characteristics of children in DS, IS, and control groups.
DS group IS group Control group
Age (years) 4.54  2.63 6.4  2.5 5.49  3.61 *p = 0.511
Sex (male/subjects) 7/12 7/17 7/15 **p = 0.692
Body mass index 14.46  3.44 15.72  2.17 15.73  3.15 *p = 0.4658
Duration (years) 3.86  2.48 3.09  1.86 N/A ***p = 0.476
Numbers of AEDs 2.58  0.49 1.47  0.61 N/A ***p = 0.000421
DS; daily seizures, IS; intermittent seizures, AEDs; antiepileptic drugs.
* Kruskal–Wallis test.
** Fisher’s exact test.
*** Mann–Whitney U test, N/A; not applicable.centrifuged (2000  g, 20 min); serum or plasma was then isolated
and stored at 80 8C for analysis within 6 h after collection. hs-
CRP, PTX3, TNF-a, IL-6, and IL-1b concentrations were determined
using commercially available kits. Hs-CRP concentrations were
measured using a nephelometry method (N-Latex CRP II, Siemens
Healthcare Diagnostics, Erlangen, Germany). PTX3 and TNF-a
concentrations were each determined using quantitative sandwich
enzyme immunoassay methods (Pentraxin 3 Quantikine for PTX3
and Quanti Glo Human TNF-a Chemiluminescent Immunoassay
2nd generation for TNF-a; R&D Systems, Minneapolis, MN, USA).
IL-6 and IL-1b concentrations were measured by ﬂuorescent bead-
based immunoassays (Novex Singleplex Luminex Assay, Life
Technologies, Carlsbad, CA, USA) based on the Luminex system
(Luminex, Austin, TX, USA). All analyses were performed according
to the manufacturers’ instructions.
2.3. Statistical analyses
Data are shown as means  standard deviation (SD), unless
stated otherwise. Statistical analyses were performed using the
statistical package ‘R’ (ver. 3.2.2; available at http://www.r-projec-
t.org). Numerical variables were compared using the Mann–Whitney
U-test. A p value <0.05 was considered to indicate statistical
signiﬁcance. To examine differences between independent groups,
the Kruskal–Wallis test and Fisher’s exact test were used for
categorical outcomes.
3. Results (Fig. 1)
Hs-CRP levels were signiﬁcantly higher in the DS group
(0.149  0.161 mg/dL) than the IS and control groups
(0.0156  0.0136 and 0.0253  0.0288 mg/dL; p < 0.005 and <0.05,
respectively), whereas there was no signiﬁcant difference between
the IS and control groups. IL-6 levels were also signiﬁcantly higher in
the DS group (8.022  0.161 pg/mL) than either the IS or control
group (7.783  0.0563 and 7.864  0.072 pg/mL; p < 0.005 and <
0.05, respectively). The number of antiepileptic drugs (AEDs) used
was signiﬁcantly higher in the DS than IS group (2.583 vs. 1.471;
p < 0.001). The PTX3 level was 0.72  0.482 ng/mL in the DS group,
0.774  0.463 ng/mL in the IS group, and 0.993  0.539 ng/mL in the
control group. Although the PTX3 level tended to be higher in the
control group, no statistically signiﬁcant difference was detected
among the three groups. The TNF-a level was 1.245  1.049 pg/mL in
the DS group, 0.672  0.537 pg/mL in the IS group, and
1.267  1.084 pg/mL in the control group. The TNF-a level also
tended to be higher in the control group, but no statistically
signiﬁcant difference was detected among the groups. The IL-1b
level was 15.663  0.0654 pg/mL in the DS group, 15.628  0.037 pg/
mL in the IS group, and 15.634  0.0331 pg/mL in the control group.
There were no statistically signiﬁcant differences among the groups.
4. Discussion
Experimental evidence indicates signiﬁcant roles for inﬂam-
matory and immune mediators in the initiation of seizures and
epileptogenesis.15–28 In particular, cytokines including IL-1b, IL-6,
and TNF-a, and Toll-like receptor 4 have been shown to contribute
to seizure generation and epileptogenesis.28,29 In addition to
experimental studies using animal models, human clinical studies
have demonstrated alterations in the levels of IL-6 in samples from
patients with epilepsy.16 However, there are few data regarding
TNF-a in patients with epilepsy, although seizures can induce the
expression of TNF-a mRNA in the brains of animal models.29
Experimental seizures were associated with post-ictal increases in
IL-1b in the CNS, while no observable differences in IL-1b
concentrations after seizure were demonstrated.16,20,30 Our results
Fig. 1. Levels of inﬂammatory markers in the DS, IS, and control groups. The centerlines indicate medians, boxes indicate 25th–75th percentiles, and whiskers indicate the
minimum and maximum values (white circles indicate outliers). DS, daily seizures, IS, intermittent seizures.
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ictal increase was seen in IL-6, which peaked at 12 h and remained
elevated at 24 h.16,17,20 The reason a signiﬁcant increase in IL-6 wasobserved in the DS group may be because the multiple generalized
motor seizures each day sustained the production of IL-6 before its
degradation/turnover.
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inﬂammatory marker produced by hepatocytes in response to
inﬂammatory cytokines, such as IL-1, IL-6, and TNF-a, or to other
stimulations.10,31 Measurement of hs-CRP levels has recently been
recognized as a method to detect chronic inﬂammation in patients
with cardiovascular diseases,1,2,32 stroke,7 renal disease,33 and
neurodegeneration diseases.5,34 PTX3 is a member of the long
pentraxins produced in peripheral tissues and monocytic phago-
cytes in response to IL-1, TNF-a, and Toll-like receptor ligands.35
In this study, we showed that hs-CRP levels in patients with
daily generalized motor seizures were signiﬁcantly higher than
those in other epilepsy patients or control subjects. These results
may indicate that frequent motor seizures can cause chronic
inﬂammation. Alapirtti et al22. suggested that secondarily gener-
alized tonic–clonic seizures stimulated CRP even though other
partial seizures did not. Peltola et al.21 reported a signiﬁcant
correlation between plasma IL-6 and CRP concentrations in
patients with recent tonic–clonic seizures. Our results suggest
that daily generalized motor seizures provoked elevation of IL-6,
leading to increased CRP levels.
Previous reports have shown that PTX3 is synthesized in the
brain after seizures and may exert a protective role against seizure-
induced neurodegeneration.23 However, while plasma PTX3 has
also been recognized as a biomarker of cardiovascular, renal
disease, and systemic autoimmune diseases,11,36–39 there is little
information about its role as a plasma biomarker in patients with
epilepsy. Although plasma PTX3 is useful for detecting vascular
inﬂammation,40 it may not be sensitive enough to provide
inﬂammation about neuronal cells. We found no signiﬁcant
difference in PTX3 levels among the three groups. These results
suggested that daily generalized motor seizures did not raise
plasma PTX3 levels; however, there may be PTX3 production
within the central nervous system.
It has been reported that AEDs may affect inﬂammatory
markers. One study that examined markers for atherosclerosis risk
in 195 epilepsy patients treated with AEDs showed higher CRP
levels compared with controls.41 Valproate is associated with
lower CRP.42 Signiﬁcantly lower CRP values have been shown to
associate with the use of lamotrigine and levetiracetam, and a
trend for higher CRP values has been reported for patients on
phenytoin and carbamazepine.43 Long-term use of AEDs generally
may result in low-grade systemic inﬂammation and increased
oxidative stress.41 In this study, there was no signiﬁcant difference
in treatment duration between the DS and IS groups. The number
of AEDs used in the DS group was signiﬁcantly greater than that in
the IS group due to the refractory clinical course of the DS group.
Yuen et al.42 demonstrated no signiﬁcant relationship between the
number of AEDs taken and CRP. Thus, the higher levels of CRP in the
DS group may be attributable to the frequent daily generalized
motor seizures.
This study has certain limitations. Although the participants
presented with no obvious inﬂammatory symptoms, CRP
concentrations may ﬂuctuate slightly over time with unnotice-
able, subtle conditions, which may affect the validity of CRP
levels.
Librizzi et al.44 reported that seizures initiate brain inﬂamma-
tion in glia and promote blood–brain barrier damage indepen-
dently of leukocytes or blood-borne inﬂammatory molecules, and
brain inﬂammation can contribute to the duration and recurrence
of seizures. In this study, we did not evaluate the intracellular
conditions of neuronal cells. Systemic inﬂammatory responses in
the intractable patients may have affected their prognoses. The
impact of systemic inﬂammatory responses on generalized motor
seizures in pediatric patients with epilepsy needs to be evaluated.
The possible utility of anti-epileptic and anti-epileptogenesis
therapies that target inﬂammation has been reported.27,45 To treatintractable epilepsy, we may have to consider therapeutic
strategies, including ways to control the inﬂammatory process too.
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